Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Q3 2025 value amounting to $7.5 million.

  • Ironwood Pharmaceuticals' Other Accumulated Expenses fell 409.21% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 409.21%. This contributed to the annual value of $4.4 million for FY2024, which is 2870.74% down from last year.
  • Ironwood Pharmaceuticals' Other Accumulated Expenses amounted to $7.5 million in Q3 2025, which was down 409.21% from $5.2 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $14.3 million for Q3 2023, and its period low was $1.9 million during Q1 2021.
  • Its 5-year average for Other Accumulated Expenses is $6.1 million, with a median of $5.2 million in 2025.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 5511.46% in 2021, then skyrocketed by 25592.33% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Other Accumulated Expenses stood at $3.4 million in 2021, then rose by 4.59% to $3.6 million in 2022, then skyrocketed by 72.14% to $6.2 million in 2023, then dropped by 28.71% to $4.4 million in 2024, then soared by 69.76% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $5.2 million for Q2 2025, and $7.5 million during Q1 2025.